Curcumin potentiates the ErbB receptors inhibitor Afatinib for enhanced antitumor activity in malignant mesothelioma

References

• Alesiani D, Cicconi R, Mattei M, Bei R, Canini A. 2009. Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells. Int J Oncol. 34(6):1727–1735. doi: 10.3892/ijo_00000303.
   PubMed Web of Science ®Google Scholar
• Agatsuma N, Yasuda Y, Ozasa H. 2017. Malignant pleural mesothelioma harboring both G719C and S768I mutations of EGFR successfully treated with afatinib. J Thorac Oncol. 12(9):e141–e143. doi: 10.1016/j.jtho.2017.04.028.
   PubMedGoogle Scholar
• Amaravadi RK, Kimmelman AC, Debnath J. 2019. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 9(9):1167–1181. doi: 10.1158/2159-8290.CD-19-0292.
   PubMed Web of Science ®Google Scholar
• Arena A, Romeo MA, Benedetti R, Masuelli L, Bei R, Gilardini Montani MS, Cirone M. 2021. New insights into curcumin- and resveratrol-mediated anti-cancer effects. Pharmaceuticals. 14(11):1068. doi: 10.3390/ph14111068.
   Web of Science ®Google Scholar
• Asciak R, George V, Rahman NM. 2021. Update on biology and management of mesothelioma. Eur Respir Rev. 30(159):200226. doi: 10.1183/16000617.0226-2020.
   PubMed Web of Science ®Google Scholar
• Baldi A, De Luca A, Maiorano P, D’Angelo C, Giordano A. 2020. Curcumin as an anticancer agent in malignant mesothelioma: a review. Int J Mol Sci. 21(5):1839. doi: 10.3390/ijms21051839.
   PubMed Web of Science ®Google Scholar
• Bei R, Benvenuto M, Focaccetti C, Fazi S, Moretti M, Nardozi D, Angiolini V, Ciuffa S, Cifaldi L, Carrano R, et al. 2022. Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo. J Transl Med. 20(1):286. doi: 10.1186/s12967-022-03490-9.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Angiolini V, Focaccetti C, Nardozi D, Palumbo C, Carrano R, Rufini A, Bei R, Miele MT, Mancini P, et al. 2023. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo. Biol Direct. 18(1):17. doi: 10.1186/s13062-023-00374-w.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Mattera R, Sticca JI, Rossi P, Cipriani C, Giganti MG, Volpi A, Modesti A, Masuelli L, Bei R. 2018. Effect of the BH3 mimetic polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo growth of malignant mesothelioma. Front Pharmacol. 9:1269. doi: 10.3389/fphar.2018.01269.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Albonici L, Focaccetti C, Ciuffa S, Fazi S, Cifaldi L, Miele MT, De Maio F, Tresoldi I, Manzari V, et al. 2020. Polyphenol-mediated autophagy in cancer: evidence of in vitro and in vivo studies. Int J Mol Sci. 21(18):6635. doi: 10.3390/ijms21186635.
   PubMed Web of Science ®Google Scholar
• Cao W, Ma J, Jiang X, Gao G. 2022. Afatinib targeted therapy affects the immune function and serum levels of EGFR and gastrin-releasing peptide precursor (pro-GRP) in patients with non-small-cell lung cancer (NSCLC). Dis Markers. 2022:2869531–2869535. doi: 10.1155/2022/2869531.
   PubMed Web of Science ®Google Scholar
• Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. 2001. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol. 159(2):721–731. doi: 10.1016/S0002-9440(10)61743-9.
   PubMed Web of Science ®Google Scholar
• Chen P, Huang HP, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG, Li J. 2019. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. J Exp Clin Cancer Res. 38(1):254. doi: 10.1186/s13046-019-1234-8.
   PubMedGoogle Scholar
• Chia PL, Parakh S, Russell P, Gan HK, Asadi K, Gebski V, Murone C, Walkiewicz M, Liu Z, Thapa B, et al. 2021. Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. Lung Cancer. 153:35–41. doi: 10.1016/j.lungcan.2020.12.028.
   PubMed Web of Science ®Google Scholar
• Chia PL, Scott AM, John T. 2019. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. Expert Opin Drug Deliv. 16(4):441–451. doi: 10.1080/17425247.2019.1598374.
   PubMed Web of Science ®Google Scholar
• Chmielewska-Kassassir M, Wozniak LA. 2021. Phytochemicals in malignant pleural mesothelioma treatment-Review on the current trends of therapies. Int J Mol Sci. 22(15):8279. doi: 10.3390/ijms22158279.
   PubMed Web of Science ®Google Scholar
• Davis A, Ke H, Kao S, Pavlakis N. 2022. An update on emerging therapeutic options for malignant pleural mesothelioma. Lung Cancer (Auckl). 13:1–12. doi: 10.2147/LCTT.S288535.
   PubMed Web of Science ®Google Scholar
• Dei Cas M, Ghidoni R. 2019. Dietary curcumin: correlation between bioavailability and health potential. Nutrients. 11(9):2147. doi: 10.3390/nu11092147.
   PubMed Web of Science ®Google Scholar
• Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, et al. 2006. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 51(2):207–215. doi: 10.1016/j.lungcan.2005.10.016.
   PubMed Web of Science ®Google Scholar
• Duggirala KB, Lee Y, Lee K. 2022. Chronicles of EGFR tyrosine kinase inhibitors: targeting EGFR C797S containing triple mutations. Biomol Ther. 30(1):19–27. doi: 10.4062/biomolther.2021.047.
   PubMed Web of Science ®Google Scholar
• Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, Leighl NB. 2018. Afatinib in advanced pretreated non-small-cell lung cancer – a Canadian experience. Curr Oncol. 25(5):e385–e390. doi: 10.3747/co.25.3914.
   PubMed Web of Science ®Google Scholar
• Fantini M, Benvenuto M, Masuelli L, Frajese GV, Tresoldi I, Modesti A, Bei R. 2015. In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment. Int J Mol Sci. 16(5):9236–9282. doi: 10.3390/ijms16059236.
   PubMed Web of Science ®Google Scholar
• Giordano A, Tommonaro G. 2019. Curcumin and cancer. Nutrients. 11(10):2376. doi: 10.3390/nu11102376.
   PubMed Web of Science ®Google Scholar
• Goodglick LA, Vaslet CA, Messier NJ, Kane AB. 1997. Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas. Toxicol Pathol. 25(6):565–573. doi: 10.1177/019262339702500605.
   PubMed Web of Science ®Google Scholar
• Ghosh C, Xing Y, Cai J, Sun Y. 2023. Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2. Biochem Biophys Rep. 34:101436. doi: 10.1016/j.bbrep.2023.101436.
   PubMedGoogle Scholar
• Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. Aaps J. 15(1):195–218. doi: 10.1208/s12248-012-9432-8.
   PubMed Web of Science ®Google Scholar
• Hocking AJ, Farrall AL, Newhouse S, Sordillo P, Greco K, Karapetis CS, Dougherty B, Klebe S. 2021. Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE). BMJ Open. 11(3):e047075. doi: 10.1136/bmjopen-2020-047075.
   PubMed Web of Science ®Google Scholar
• Huang L, Cai M, Zhang X, Wang F, Chen L, Xu M, Yang K, Chen Z, Wang X, Fu L. 2017. Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. Am J Cancer Res. 7(2):203–217.
   PubMed Web of Science ®Google Scholar
• Huang L, Fu L. 2015. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 5(5):390–401. doi: 10.1016/j.apsb.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Jakobsen JN, Sørensen JB. 2011. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol. 68(1):1–15. doi: 10.1007/s00280-011-1655-3.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. 2013. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 54(6):936–943. doi: 10.2967/jnumed.112.110239.
   PubMed Web of Science ®Google Scholar
• Karaboga Arslan AK, Uzunhisarcikl E, Yerer MB, Bishayee A. 2022. The golden spice curcumin in cancer: a perspective on finalized clinical trials during the last 10 years. J Cancer Res Ther. 18(1):19–26. doi: 10.4103/jcrt.JCRT_1017_20.
   PubMed Web of Science ®Google Scholar
• Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, et al. 2017. Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett. 393:52–59. doi: 10.1016/j.canlet.2017.02.015.
   PubMed Web of Science ®Google Scholar
• Kubczak M, Szustka A, Rogalińska M. 2021. Molecular targets of natural compounds with anti-cancer properties. Int J Mol Sci. 22(24):13659. doi: 10.3390/ijms222413659.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Koyama S, Nishikawa H. 2021. Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 21(3):181–197. doi: 10.1038/s41568-020-00322-0.
   PubMed Web of Science ®Google Scholar
• Marquez-Medina D, Popat S. 2015. Afatinib: a second-generation EGFR receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future Oncol. 11(18):2525–2540. doi: 10.2217/fon.15.183.
   PubMed Web of Science ®Google Scholar
• Masuelli L, Benvenuto M, Di Stefano E, Mattera R, Fantini M, De Feudis G, De Smaele E, Tresoldi I, Giganti MG, Modesti A, et al. 2017. Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. Oncotarget. 8(21):34405–34422. doi: 10.18632/oncotarget.14907.
   PubMedGoogle Scholar
• Masuelli L, Granato M, Benvenuto M, Mattera R, Bernardini R, Mattei M, d’Amati G, D’Orazi G, Faggioni A, Bei R, et al. 2017. Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice. Oncoimmunology. 6(11):e1356151. doi: 10.1080/2162402X.2017.1356151.
   PubMed Web of Science ®Google Scholar
• Masuelli L, Marzocchella L, Focaccetti C, Tresoldi I, Palumbo C, Izzi V, Benvenuto M, Fantini M, Lista F, Tarantino U, et al. 2012. Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci. 17(2):498–508. doi: 10.2741/3940.
   Google Scholar
• Okita R, Shimizu K, Nojima Y, Yukawa T, Maeda A, Saisho S, Nakata M. 2015. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells. Oncol Rep. 34(6):2864–2870. doi: 10.3892/or.2015.4314.
   PubMed Web of Science ®Google Scholar
• Palumbo C, Bei R, Procopio A, Modesti A. 2008. Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem. 15(9):855–867. doi: 10.2174/092986708783955446.
   PubMed Web of Science ®Google Scholar
• Palumbo C, Mecchia A, Bocedi A, Aquilano K, Lettieri-Barbato D, Rosina M, Di Venere A, Rodolfo C, Caccuri AM. 2022. Revisited role of TRAF2 and TRAF2 C-terminal domain in endoplasmic reticulum stress-induced autophagy in HAP1 leukemia cells. Int J Biochem Cell Biol. 145:106193. doi: 10.1016/j.biocel.2022.106193.
   PubMed Web of Science ®Google Scholar
• Patel SS, Acharya A, Ray RS, Agrawal R, Raghuwanshi R, Jain P. 2020. Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr. 60(6):887–939. doi: 10.1080/10408398.2018.1552244.
   PubMed Web of Science ®Google Scholar
• Paul S, Sa G. 2021. Curcumin as an adjuvant to cancer immunotherapy. Front Oncol. 11:675923. doi: 10.3389/fonc.2021.675923.
   PubMedGoogle Scholar
• Pouliquen DL, Nawrocki-Raby B, Nader J, Blandin S, Robard M, Birembaut P, Grégoire M. 2017. Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma. Oncotarget. 8(34):57552–57573. doi: 10.18632/oncotarget.15744.
   PubMedGoogle Scholar
• Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A. 1987. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res. 47(12):3199–3205.
   PubMed Web of Science ®Google Scholar
• Rossini M, Rizzo P, Bononi I, Clementz A, Ferrari R, Martini F, Tognon MG. 2018. New perspectives on diagnosis and therapy of malignant pleural mesothelioma. Front Oncol. 8:91. doi: 10.3389/fonc.2018.00091.
   PubMed Web of Science ®Google Scholar
• Santarelli R, Farina A, Granato M, Gonnella R, Raffa S, Leone L, Bei R, Modesti A, Frati L, Torrisi MR, et al. 2008. Identification and characterization of the product encoded by ORF69 of Kaposi’s sarcoma-associated herpesvirus. J Virol. 82(9):4562–4572. doi: 10.1128/JVI.02400-07.
   PubMed Web of Science ®Google Scholar
• Sayeed MA, Bracci M, Lucarini G, Lazzarini R, Di Primio R, Santarelli L. 2017. Regulation of microRNA using promising dietary phytochemicals: possible preventive and treatment option of malignant mesothelioma. Biomed Pharmacother. 94:1197–1224. doi: 10.1016/j.biopha.2017.07.075.
   PubMed Web of Science ®Google Scholar
• Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O’Byrne KJ, Testa JR, Pass HI, Faux SP, et al. 2011. An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol. 45(5):906–914. doi: 10.1165/rcmb.2010-0282OC.
   PubMed Web of Science ®Google Scholar
• Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM. 2000. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology. 36(6):522–528. doi: 10.1046/j.1365-2559.2000.00888.x.
   PubMed Web of Science ®Google Scholar
• Tu HF, Ko CJ, Lee CT, Lee CF, Lan SW, Lin HH, Lin HY, Ku CC, Lee DY, Chen IC, et al. 2021. Afatinib exerts immunomodulatory effects by targeting the pyrimidine biosynthesis enzyme CAD. Cancer Res. 81(12):3270–3282. doi: 10.1158/0008-5472.CAN-20-3436.
   PubMed Web of Science ®Google Scholar
• Vavalà T. 2017. Role of afatinib in the treatment of advanced lung squamous cell carcinoma. Clin Pharmacol. 9:147–157. doi: 10.2147/CPAA.S112715.
   PubMed Web of Science ®Google Scholar
• Velcheti V, Kasai Y, Viswanathan AK, Ritter J, Govindan R. 2009. Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol. 4(4):559. doi: 10.1097/JTO.0b013e31819c8661.
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. 2006. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 1(3):1112–1116. doi: 10.1038/nprot.2006.179.
   PubMed Web of Science ®Google Scholar
• Visci G, Rizzello E, Zunarelli C, Violante FS, Boffetta P. 2022. Relationship between exposure to ionizing radiation and mesothelioma risk: a systematic review of the scientific literature and meta-analysis. Cancer Med. 11(3):778–789. doi: 10.1002/cam4.4436.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu J, Jiang B, Guo J. 2020. The roles of curcumin in regulating the tumor immunosuppressive microenvironment. Oncol Lett. 19(4):3059–3070. doi: 10.3892/ol.2020.11437.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, et al. 2015. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget. 6(32):33602–33611. doi: 10.18632/oncotarget.5286.
   PubMedGoogle Scholar